Ninety-one percent of nearly 250 emergency physicians surveyed in a new ACEP poll said they had experienced a shortage or absence of critical medicine in their emergency department in the past month. That increases costs and compromises care.
In laying out the Trump administration's strategy for reducing drug prices, HHS Secretary Alex Azar suggested pumping up Medicare Part D by moving some expensive drugs out of Part B.
Women who use the breast cancer drug Herceptin for six months did just as well as those who took it for a year, according to a new study that could ultimately benefit value-based providers and harm those still based on fee-for-service models.
The FDA claimed 39 drug companies may be blocking generic-drug makers from obtaining samples of their branded products to hinder generic competition.
The Icahn School of Medicine at Mount Sinai has created a $10 million accelerator fund to speed up the commercialization of research at the school. It's starting with two investments in drug-development ventures.
The FDA is exploring whether it can legally force drugmakers to disclose prices in consumer advertising. President Donald Trump has called the move a key strategy to give companies incentives to keep prices low.
The Senate health committee took hospitals out of the 340B hot seat to focus on pharmaceutical companies. Lawmakers wanted to know how much drugmakers may be overcharging 340B hospitals for discounted drugs.
HHS Secretary Alex Azar promised to use his "very powerful pen" to upend Medicare Part B's payment structure as his agency asked providers and pharmaceutical companies to weigh in on 340B changes.
As the opioid epidemic continues to spread, UCHealth in Colorado took the unusual step of instituting random drug testing for its 21,000 employees. CEO Elizabeth Concordia discusses that strategy in this Q&A.
HHS Secretary Alex Azar said HHS is focused on finding solutions for the "lack of negotiating tools" that cause government programs and seniors to overpay for drugs and out-of-pocket costs and lead to "foreign governments free-riding" off U.S. innovation.
Fentanyl and other synthetic opioids killed more people than prescription opioids in 2016, marking a new phase in the opioid crisis.
As pharmaceutical companies develop digital tools to combat medication adherence issues, the Food and Drug Administration is considering regulating them.